西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较

Comparison of therapeutic effects of sitagliptin versus acarbose for newly-diagnosed T2DM patients

目的观察DPP-4抑制剂西格列汀对新诊断T2DM患者的疗效。方法 40例新诊断的T2DM患者被随机分成两组,分别给予西格列汀和阿卡波糖单药治疗。结果 12周治疗后两组HbA1c、FPG、2hPG及体重均明显减低,组间比较差异无统计学意义(P>0.05)。西格列汀组治疗后胰岛β细胞功能指数(HOMA-β)明显升高(P<0.01),阿卡波糖组胰岛素抵抗指数(HOMA-IR)和血脂谱明显改善(P<0.05)。结论西格列汀是一种安全有效的新型降糖药物。

Objective To observe the efficacy of DPP-4 inhibitor sitagliptin for newly-diagnosed T2DM patients.Methods Forty T2DM patients were randomly assigned to 2 groups: group A receiving sitagliptin 100 mg and group B receiving acarbose 150～300 mg daily.Results After the 12-week treatment,the levels of HbA1c,FPG,2 hPG,and body weight decreased significantly as compared to baseline in both groups,and there was no significant difference between the 2 groups(P>0.05).HOMA-β increased significantly in the sitagliptin group(P<0.01) and HOMA-IR and lipid profile were improved in the acarbose group(P<0.05).Conclusion Sitagliptin is an effective and safe new medicine in reducing plasma glucose.